医師の一分

アクセスカウンタ

zoom RSS 新たなSLE治療薬Benlystaが認可/米国 FDA

<<   作成日時 : 2011/03/11 23:47   >>

なるほど(納得、参考になった、ヘー) ブログ気持玉 2 / トラックバック 0 / コメント 0

 ここ半世紀ではじめて新たなSLE治療薬Benlystaが認可された。
 2015年には世界で年間50億ドル近い売上げとなるだろうと予測されている。
 FDAは標準的な治療を受けている活動的なSLEの患者に適応とした。治験では治療に反応しない黒人患者がいたが、はっきりした結論をだすほどの患者数ではないので、発売後の追跡研究が必要である。
 重症腎症や中枢神経障害合併例にはこの薬剤の治療は推奨されない。
 使用者にはプラセーボと比べて死亡者数や重症感染合併が多かった。
 世界で約500万人がこの疾患にかかっている。現在のステロイド類の治療薬では治療がうまくいかなかったり、骨粗鬆など重度の副作用をおこす。Benlystaでより副作用少なく有効な治療ができる可能性があるという。
 企業資金による研究によれば、通常の治療に加えて高容量のBenlystaをおこなうと、43%の人は1年後にさらなる臓器障害なしに症状の軽減がはかれた。一方で、プラセーボ群では約34%だった。
 薬剤費は年間約35,000ドルと他の自己免疫疾患のバイオテクノロジー医療に近い価格がかかる。1ヶ月に1回静注により薬剤は投与される。
 2015年には20億ドルの売上げが予測されている。

Belimumab (Benlysta、抗 B-lymphocyte stimulator(BLyS) モノクロナール抗体)
------------------------------------------------------
FDA clears new lupus drug, blockbuster sales seen
http://www.reuters.com/article/2011/03/10/us-humangenome-lupus-idUSTRE7287JY20110310

By Lisa Richwine

WASHINGTON | Thu Mar 10, 2011 10:13am EST

WASHINGTON (Reuters) - The first new treatment for lupus in a half-century won U.S. approval on Wednesday, a milestone for patients with the disabling disease and a potential blockbuster for its tiny biotech maker.

Health officials cleared Benlysta, discovered by Human Genome Sciences Inc, to combat the disease that causes the immune system to attack joints and organs and has proved tough to study and treat.

Shares of Human Genome, a money-losing company founded in 1992 to develop drugs with data from the human genetic map, were halted. The company will split profits with British drug giant GlaxoSmithKline Plc.

Glaxo shares rose 3.4 percent in after-hours trading to $39.90, up from an earlier close of $38.58 in regular trading on the New York Stock Exchange.

Benlysta's annual global sales may top $3 billion in 2015, according to Thomson Reuters consensus forecasts. Some analysts predict sales as high as $5 billion in later years.

For doctors and patients, Benlysta is a welcome advance after decades with few good options and a string of research failures.

"It is a big success. It opens the way for more FDA-approved lupus drugs," Dr. Anca Askanase of the New York University School of Medicine and the NYU Hospital for Joint Diseases said in an interview.

The Food and Drug Administration approved Benlysta for certain patients with active lupus who are receiving standard therapy.

It said black patients "did not appear to respond to treatment" with Benlysta in clinical trials but added that studies "lacked sufficient numbers to establish a definite conclusion."

The FDA did not warn against use in black patients, as some investors feared, but instead required the company to run a post-approval study in blacks.

IMPORTANT NEW TREATMENT

Use is not recommended for patients with lupus that has caused severe kidney or central nervous system problems, the makers said in a statement.

More deaths and serious infections were reported with Benlysta compared with a placebo in clinical studies. The FDA required a patient-friendly guide explaining the risks.

"Benlysta, when used with existing therapies, may be an important new treatment approach ...to help manage symptoms," said Dr. Curtis Rosebraugh, head of the FDA office that reviewed the drug.

Lupus causes a range of symptoms including arthritis, kidney damage, chest pain, skin rashes, severe fatigue and other problems. Symptoms often wax and wane. The organ damage can be fatal.

An estimated 5 million people worldwide have the disease. Current drugs often fail to help or cause harsh side effects, such as severe bone loss from steroids.

"That is what makes it really important with Benlysta - the possibility of having a successful treatment that is less toxic than the drugs we normally use. They can really play havoc on the body," said Benjamin Pruitt, a 50-year-old educator and musician from Falls Church, Virginia, who has been living with lupus for over 25 years.

RELIEF WITH NO ORGAN DAMAGE

One company-funded study showed 43 percent of patients given a high Benlysta dose with standard therapies felt relief and had no further organ damage after one year of treatment. That compared with nearly 34 percent with a placebo and standard care, which includes immunosuppressant drugs such as Roche's CellCept and steroids such as prednisone.

The drug will cost the average patient about $35,000 annually, a price in line with other biotech medicines for autoimmune diseases, Barry Labinger, Human Genome's chief commercial officer, said on a conference call.

The companies expect Benlysta will be available in about two weeks.

Benlysta has revived Human Genome, a company that struggled to capitalize on excitement about the mapping of the human genome.

Several of the company's drugs failed in clinical trials, and investors largely wrote off Benlysta after mixed early data. Its shares fell below 50 cents in March 2009 but jumped later that year when the first encouraging Benlysta data was released.

Now, the company is an industry star and takeover target for partner Glaxo or other big drugmakers, analysts said.

Benlysta, known generically as belimumab, is given once a month by intravenous infusion.

Sanford Bernstein analyst Geoffrey Porges said the product could reach $2 billion in sales by 2015 or later. "But they are going to have to ramp up production of the product pretty quickly. The initial adoption is going to be fairly modest this year," he said.

The company expects European approval for the drug in the second half of the year.

(Reporting by Lisa Richwine in Washington, Bill Berkrot in New York and Deena Beasley in Los Angeles; Editing by Tim Dobbyn)


テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ
気持玉数 : 2
なるほど(納得、参考になった、ヘー) なるほど(納得、参考になった、ヘー)

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
新たなSLE治療薬Benlystaが認可/米国 FDA 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる